[Current trends in the chemotherapy of cancer].
D000284:Administration, Oral; D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000963:Antimetabolites / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D006728:Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*
D000477:Alkylating Agents; D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D006728:Hormones; D011868:Radioisotopes; D014748:Vinca Alkaloids; D001215:Asparaginase
Tendencias actuales en la quimioterápia del cáncer